Our current study, conducted in a nationally representative sample of older adults with T2D in Medicare, is one of the first to investigate the effectiveness of SGLT2 inhibitors in reducing the risk of incident AF in the US population and contributes to a better understanding of the potential benefits of SGLT2 inhibitors in AF risk reduction. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.